Latest Rituximab Stories
New report from Kantar Health shows opportunities for biosimilars are high in oncology, low in rheumatoid arthritis in China. Shanghai, China (PRWEB) December
- Anthera to receive up to $48,000,000 plus future product margin on commercial supply HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
Comprehensive market research report “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment
DALLAS, October 29, 2014 /PRNewswire/ -- ReportsnReports.com adds Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline
ChinaMarketResearchReports.com adds Latest Report on “Global and China Monoclonal Antibody Industry Report, 2014-2019” to its store.
- A political dynamiter.